Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. decreased its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 39.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 102,993 shares of the company’s stock after selling 67,352 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Structure Therapeutics were worth $7,163,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its holdings in Structure Therapeutics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after acquiring an additional 106,389 shares in the last quarter. Casdin Capital LLC raised its holdings in Structure Therapeutics by 26.9% in the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after acquiring an additional 330,000 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Structure Therapeutics by 63.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock valued at $89,317,000 after acquiring an additional 496,726 shares in the last quarter. Millennium Management LLC raised its holdings in Structure Therapeutics by 4.5% in the third quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after acquiring an additional 54,496 shares in the last quarter. Finally, Orbimed Advisors LLC raised its holdings in Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock valued at $24,873,000 after acquiring an additional 397,272 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on GPCR shares. HC Wainwright reduced their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 16th. BMO Capital Markets set a $145.00 target price on shares of Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. Canaccord Genuity Group began coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $109.25.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $39.19 on Tuesday. The firm’s fifty day simple moving average is $46.46 and its 200-day simple moving average is $56.85. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -45.05 and a beta of -1.31. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.29 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.